ICR , a leading strategic communications and advisory firm, is pleased to announce that Mei Mei Hu, Chief Executive Officer and Co-Founder, Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...
Investors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one.
Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312 Phase 1 Part B Trial for Parkinson’s...
Summit is taking place July 26, 2022 from 11:00 AM ET – 3:15 PM ET The White House Summit on the Future of COVID-19 Vaccines live webcast can be accessed...
DALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic...
OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq:...
DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic...
DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic...
Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at...